In this research, we reported the prognostic value of a novel peripheral indicator “platelet‐to‐neutrophil ratio (PNR)” in cases with R/R cHL after treated with anti‐PD‐1‐based immunotherapy and further validated in other solid tumor patients. Here, PDCD1 is linked to classic Hodgkin lymphoma.